T cell receptor peptide therapy for autoimmune disease

Area of Science:

• Immunology
• Neuroimmunology
• Autoimmunity

Background:

• Experimental autoimmune encephalomyelitis (EAE) in rats shares similarities with human multiple sclerosis (MS).
• Encephalitogenic T cells play a crucial role in the pathogenesis of EAE and potentially MS.
• T cell receptor (TCR) V beta sequences are implicated in the autoimmune response.

Purpose of the Study:

• To investigate the therapeutic potential of synthetic TCR peptides in autoimmune diseases.
• To elucidate the mechanism of action for TCR peptide-based immunotherapy.
• To assess the safety and efficacy of TCR peptide therapy in preclinical models and preliminary human trials.

Main Methods:

• Administration of synthetic peptides corresponding to germline TCR V beta sequences in rats with EAE.
• Monitoring of disease progression, T cell responses, and antibody production.
• Analysis of TCR V gene usage in T cells reactive to myelin antigens.
• Preliminary human trials evaluating safety and immune response to TCR peptides.

Main Results:

• Synthetic TCR peptides prevented and treated EAE in rats.
• The treatment induced anti-TCR immunity, leading to autoregulatory T cells and antibodies.
• Human trials demonstrated safe and efficient boosting of anti-TCR immunity with loss of disease-specific T cell response.

Conclusions:

• Synthetic TCR peptides represent a viable strategy for selective immunotherapy in autoimmune diseases.
• The findings suggest a potential new treatment avenue for multiple sclerosis by targeting TCRs.
• Boosting anti-TCR immunity offers a promising approach for regulating autoimmune responses in humans.